

# THOMSON REUTERS INTEGRITY

QUICK GUIDE SERIES: No. 13



## THOMSON REUTERS DRUG NEWS AS A STARTING POINT FOR IN-DEPTH INVESTIGATION IN THOMSON REUTERS INTEGRITY

In this quick guide we showcase how subscribers to both *Thomson Reuters Drug News* and *Thomson Reuters Integrity*<sup>SM</sup> can make the most of cross-linking these valuable databases in their daily research activities.

Stay abreast of early-stage drug research and development news with *Thomson Reuters Drug News*, and use *Drug News* as a launch pad for additional investigation in *Integrity*. As a *Drug News* subscriber, receive daily headline alerts via e-mail and benefit from a simple one-click process to start your research.

Link from *Drug News* to *Integrity* and drill down into the comprehensive collection of curated scientific data covering the biology, chemistry, pharmacology, PK, and clinical aspects of drug R&D.

This step-by-step guide will show you how to:

- Link from a *Drug News* news item to the relevant *Integrity* record
- Find all related information to a particular record available in *Integrity*
- Easily export the records retrieved into an *Integrity Report*

### EXAMPLE SCENARIO: THOMSON REUTERS DRUG NEWS AS A STARTING POINT FOR IN-DEPTH INVESTIGATION IN THOMSON REUTERS INTEGRITY

A scientist sees an interesting headline about a compound with a novel inhibitor in his or her *Thomson Reuters Drug News* daily headlines e-mail alert and wants to investigate further. The compound has the same mechanism of action as a compound that his organization is developing.

#### 1. LINK FROM A DRUG NEWS ITEM TO THE RELEVANT INTEGRITY RECORD

- Any news source can be the starting point for in-depth investigation in *Integrity*, but with a *Drug News* subscription you can benefit from cross-linking with *Integrity* to review all relevant information on a drug of interest.
- Activate an e-mail alert for your *Drug News* subscription to receive a daily list of headlines of the latest drug R&D news. From the alert, click the title of an article of interest to go to the full article in *Drug News* (Figures 1 and 2).
- It is then a simple one-click process to move to the relevant *Integrity* record (you'll be asked to log in to *Integrity* if you don't have cookie-enabled access). The hyperlink to *Integrity* is found at the end of the full *Drug News* article and takes users directly to the relevant record(s) in *Integrity*.

#### Tip:

- *Drug News* subscribers can log in to the service and set up e-mail preferences to receive a daily e-mail alert of all headlines or just those for specific therapeutic areas.
- Once in *Integrity*, the product record provides information about the compound in the news. You will find the Highest Phase, Organization, Mechanism of Action and other relevant information, as well as links to related information in other Knowledge Areas. Click the Related Information links at the bottom of the record to go directly the associated records (Figure 3).

#### Tip:

- *Drug News* articles also include links to biomarker records in the *Biomarkers Module* of *Integrity*.

ARTICLE LIST

- AIDS  
Tue Oct 04, 2011 | Section: AIDS  
Enrollment completed in GeoVax's HIV/AIDS vaccine study
- CANCER  
Tue Oct 04, 2011 | Section: Cancer  
Array BioPharma reports results from selumetinib NSCLC study  
Tue Oct 04, 2011 | Section: Cancer  
Kancera products show activity against pancreatic cancer cells  
Tue Oct 04, 2011 | Section: Cancer  
MedImmune in-licenses tremelimumab from Pfizer  
**Tue Oct 04, 2011 | Section: Cancer  
New TTK inhibitors synthesized by Bayer Schering Pharma**  
Tue Oct 04, 2011 | Section: Cancer  
Threshold Pharmaceuticals begins pivotal study of TH-302  
Tue Oct 04, 2011 | Section: Cancer  
Update on Adventix's NDA for Exalbine  
Tue Oct 04, 2011 | Section: Cancer  
Vernalis and Servier reach milestone in oncology collaboration

FIGURE 1

CANCER NEWS ARTICLE

New TTK inhibitors synthesized by Bayer Schering Pharma  
Tue Oct 04, 2011 | Section: Cancer

Bayer Schering Pharma has prepared novel indazopyrazines with activity as dual specificity protein kinase TTK (TTK/MPS1; Btk-1) inhibitors that are reported to be useful for the treatment of cancer. An exemplified compound inhibited recombinant human TTK with an IC50 of 3.7 nM (WO 201113862).

O=C1N2C(=O)N(C1)C3=CC=C(C=C3)N4C=NC(=C4)S5CCCCO5

WO 201113862

Integrity  
Open & explore | @ an external link

FIGURE 2



THOMSON REUTERS™

## 2. WORKING WITH YOUR DATA

- Having reviewed at the product record, you can now further investigate compounds that have the same mechanism of action by running a search in the Advanced Search Form in the Drugs & Biologics Knowledge Area. Select the Mechanism of Action search field and then open the Index and select the mechanism of interest (Figure 4).
- The results list displays a list of compounds that have been reported to have the specified mechanism (Figure 5).
- Use Filter by Statistics to see the organizations that are developing the compounds and use the development status filter to see the phase of development (Figure 6).
- From this results set you can now create an *Integrity Report*. From the Options pulldown menu select *Integrity Reports* and then Product report. Give your report a name and then click Generate. You will find the Word document in the Reports tab at the top of the page (Figure 7).
- The report compiles information about all the products including the related information from different Knowledge Areas for further examination in one comprehensive document

**Tip:**

- A sample of the daily *Drug News* headlines is selected for relevance by our editorial experts and can be viewed on the *Integrity* home page under the heading Today's News (Figure 8).

Entry Number	Highest Phase	Code Name	Generic Name	Brand Name	Product Category	Therapeutic Group	Mechanism of Action	Organization
634054	Biological Testing				Oncolytic Drugs	Oncolytic Drugs	TKF Protein Kinase Inhibitors	AstraZenca (Originator)
634054	Biological Testing				Oncolytic Drugs	Oncolytic Drugs	TKF Protein Kinase Inhibitors	AstraZenca (Originator)
634054	Biological Testing				Oncolytic Drugs	Oncolytic Drugs	TKF Protein Kinase Inhibitors	AstraZenca (Originator)
634054	Biological Testing				Oncolytic Drugs	Oncolytic Drugs	TKF Protein Kinase Inhibitors	AstraZenca (Originator)
634071	Biological Testing				Oncolytic Drugs	Oncolytic Drugs	TKF Protein Kinase Inhibitors	AstraZenca (Originator)
661192	Precinical	MPI-0479605			Oncolytic Drugs	Oncolytic Drugs	Apoptosis Inducers	Novartis (Originator)
679639	Precinical	MIS-P-715			Oncolytic Drugs	Oncolytic Drugs	TKF Protein Kinase Inhibitors	Novartis (Originator)
682177	Biological Testing				Antiarthritic Drugs	Antiarthritic Drugs	TKF Protein Kinase Inhibitors	Novartis (Originator)

FIGURE 5




FIGURE 6

**Records Retrieved** 1 in Drugs & Biologics

**Drugs & Biologics Search Results**

Entry Number: 745990 | Chemical Structure | STRUCTURE PARTURES

Molecular Formula: C<sub>26</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub>S  
Molecular Weight: 458.575  
Highest Phase: Biological Testing

**Chemical Name/Description**  
N-Cyclopropyl-4-[8-(4-hydroxybutylsulfanyl)-6-phenylimidazo[1,2-a]pyrazin-3-yl]benzamide

**Standard InChI**  
19:1C26H26N4O2S:14-4-6-15-33-25-24-27-15-23(30(24)17:22(28-29)18-8-2-1-3-7-18)19-9-10-20(11-9-19)25(32)28-21-12-13-21-1-3-6-11-18-17,21,31H,4-6,12-15H2,1H,28,32)

**Standard InChIKey**  
RPTPSKRGRIWJUQP-UHFFFAOYSA-N

**Code Name** | **Generic Name** | **Brand Name**

**Molecular Mechanism** | **Cellular Mechanism**  
TKF Protein Kinase Inhibitors

**Product Category** | **Therapeutic Group** | **Prescription/ Indication Type**  
Oncolytic Drugs

**Organization**  
Bayer Schering Pharma (Originator)

**Product Summary** | **Related Information**

FIGURE 3

**Drugs & Biologics**

Home | Support/Help | Query Manager / Alert Center | Reports

FIGURE 7

**Integrity** Empowering knowledge-based drug discovery and development

**Knowledge Area** | **Quick Search**

Drugs & Biologics | Targets & Pathways | Genomics | Biomarkers | Organic Synthesis | Experimental Pharmacology | Pharmacokinetics/Metabolism | Clinical Studies | Disease Briefings | Companies & Research Institutions | Literature | Patents

Quick Access to Key Drugs & Biologics Information  
Drug Name Search | Index | IP

Quick Access to Pipeline Information  
Gateways to Development Status | Condition Lookup

**Highlights** | October 13 - 13, 2011

**Today's News**

- Berenson funds gains rights to TCI anti-hepatocellular carcinoma candidate Psychiatric Disorders
- Novartis pharmaceuticals partners with Shire Partner for Adverse Cancer
- Bristol-Myers Squibb negotiates strategy for Bristol-Myers Squibb in follicular lymphoma
- Millennium continues to look for biotech
- Bristol-Myers Squibb continues to look for biotech
- FDA approves anti-Cx36 for new indications

FIGURE 8

**Advanced Search** | Session History | Clear Form | Start

**Product** | Structure Search

Lead Compounds  Under Active Development

Mechanism of Action: TTK Protein Kinase Inhibitors | Index AND

Optional Value: | Index AND

Optional Value: | Index AND

FIGURE 4

Click here to view other guides in the *Integrity Quick Guide series*.

If you have any questions about using *Integrity*, please contact us at: [integritysupport@thomsonreuters.com](mailto:integritysupport@thomsonreuters.com)

